GoAI
Get started
LENSAR Inc logo

LENSAR Inc

LNSR

NASDAQHealthcareMedical - Devices

Open in GoAI

Previous close

$8.68

+$0.24 · +2.84%

Aug 21, 4:00 PM ET

LNSR company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

76

Undervalued

Momentum

28

Weakening

Sentiment

60

Mixed

Risk resilience

30

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing laser systems for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism in the United System, Europe, Asia, South Korea, and internationally. The company offers the LENSAR Laser System, which incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes by providing imaging, procedure planning, design, and precision. It also provides ALLY Robotic Cataract Laser System, a compact cataract treatment system that is designed to allow surgeons to perform sterile laser-assisted cataract surgery in a single operating room. LENSAR, Inc. was incorporated in 2004 and is headquartered in Orlando, Florida.

Industry
Medical - Devices
Sector
Healthcare
Headquarters
US
CEO
Nicholas T. Curtis
Listed since
Oct 2, 2020
Employees
150

Market position

Day range

Current $8.68

52-week range

Current $8.68

Open
$8.38
Previous close
$8.44
Volume
167.32K
1.65× average
Average volume
101.51K
Average daily volume
Market cap
106.6M USD
Beta
0.88
Market reference 1
50-day average
$6.1533
+41.06% above average
200-day average
$8.4468
+2.76% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
128.83M USD
EV / EBITDA
-4.33×
Earnings yield
-24.65%
Free cash flow yield
-10.72%

Profitability & efficiency

Return on equity
131.75%
Return on assets
-47.99%
Return on invested capital
-77.77%

Financial health

Current ratio
1.15×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends68%22%-24%-70%Gross margin, FY2021: 51.75%Gross margin, FY2022: 56.44%Gross margin, FY2023: 50.06%Gross margin, FY2024: 48.33%Gross margin, FY2025: 46.41%Operating margin, FY2021: -57.03%Operating margin, FY2022: -57.06%Operating margin, FY2023: -29.00%Operating margin, FY2024: -19.94%Operating margin, FY2025: -42.06%Net margin, FY2021: -56.88%Net margin, FY2022: -56.32%Net margin, FY2023: -34.11%Net margin, FY2024: -58.71%Net margin, FY2025: -58.66%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 51.75%. Gross margin FY2022 56.44%. Gross margin FY2023 50.06%. Gross margin FY2024 48.33%. Gross margin FY2025 46.41%. Operating margin FY2021 -57.03%. Operating margin FY2022 -57.06%. Operating margin FY2023 -29.00%. Operating margin FY2024 -19.94%. Operating margin FY2025 -42.06%. Net margin FY2021 -56.88%. Net margin FY2022 -56.32%. Net margin FY2023 -34.11%. Net margin FY2024 -58.71%. Net margin FY2025 -58.66%.

Income trends

Revenue

58.44M USD+9.24%

Operating income

−24.58M USD-130.45%

Net income

−34.28M USD-9.16%
Income trends across reported periods67.71M USD30.62M USD−6.47M USD−43.55M USDRevenue, FY2021: 34.46M USDRevenue, FY2022: 35.36M USDRevenue, FY2023: 42.16M USDRevenue, FY2024: 53.49M USDRevenue, FY2025: 58.44M USDOperating income, FY2021: −19.65M USDOperating income, FY2022: −20.18M USDOperating income, FY2023: −12.23M USDOperating income, FY2024: −10.67M USDOperating income, FY2025: −24.58M USDNet income, FY2021: −19.6M USDNet income, FY2022: −19.91M USDNet income, FY2023: −14.38M USDNet income, FY2024: −31.4M USDNet income, FY2025: −34.28M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 34.46M USD. Revenue FY2022 35.36M USD. Revenue FY2023 42.16M USD. Revenue FY2024 53.49M USD. Revenue FY2025 58.44M USD. Operating income FY2021 −19.65M USD. Operating income FY2022 −20.18M USD. Operating income FY2023 −12.23M USD. Operating income FY2024 −10.67M USD. Operating income FY2025 −24.58M USD. Net income FY2021 −19.6M USD. Net income FY2022 −19.91M USD. Net income FY2023 −14.38M USD. Net income FY2024 −31.4M USD. Net income FY2025 −34.28M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue58.44M USD53.49M USD42.16M USD35.36M USD34.46M USD
Cost of goods sold31.31M USD27.64M USD21.06M USD15.4M USD16.63M USD
Gross profit27.12M USD25.85M USD21.11M USD19.96M USD17.83M USD
Research and development5.62M USD5.33M USD6.14M USD11.81M USD12.36M USD
Selling, general, and administrative45.16M USD26.49M USD26.1M USD27.17M USD23.89M USD
Operating expenses51.7M USD36.52M USD33.34M USD40.13M USD37.49M USD
Interest income91K USD103K USD85K USD17K USD34K USD
Depreciation and amortization4.5M USD3.93M USD3.52M USD3.41M USD2.76M USD
Operating income−24.58M USD−10.67M USD−12.23M USD−20.18M USD−19.65M USD
Net income−34.28M USD−31.4M USD−14.38M USD−19.91M USD−19.6M USD

Company facts updated Aug 24, 2026.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Recent analyst actions

2 institutions

LNSR peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding LNSR

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
1.38M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
573.6K
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Micro-Cap ETF logoiShares Micro-Cap ETFIWC
Market value
278.04K
Weight
0.02%
AUM
1.53B USD
Expense ratio
0.60%
Price / 1D
$198.39+1.10%
U.S. Micro Cap Portfolio ETF logoU.S. Micro Cap Portfolio ETFDFMC
Market value
192.58K
Weight
0.00%
AUM
8.06B USD
Expense ratio
0.43%
Price / 1D
$60.95+0.73%
Dimensional - US Small Cap ETF logoDimensional - US Small Cap ETFDFAS
Market value
139.75K
Weight
0.00%
AUM
15.92B USD
Expense ratio
0.26%
Price / 1D
$83.02+0.73%
Avantis U.S. Small Cap Equity ETF logoAvantis U.S. Small Cap Equity ETFAVSC
Market value
8.52K
Weight
—
AUM
3.16B USD
Expense ratio
0.25%
Price / 1D
$73.84+0.70%
Dimensional - US Core Equity 1 ETF logoDimensional - US Core Equity 1 ETFDCOR
Market value
33.76
Weight
0.00%
AUM
3.51B USD
Expense ratio
0.14%
Price / 1D
$84.54+0.42%

Continue in GoAI

Research LNSR

research.disclaimer